You are here

Orion's and Bayer's darolutamide shows substantial efficacy and a favourable safety profile in the treatment of prostate cancer in the ARAMIS trial

Orion Corporation                                                                            Press ReleaseCommunications                                                                              14 February 2019 at 11.45 p.m. EET
Thursday, February 14, 2019 - 16:46